Stephen Poor

Company: Novartis

Job title: Executive Director & Head of Global Program Clinical

Seminars:

Panel & Live Audience Discussion: Optimizing Drug Delivery to the Retina 10:00 am

Topical Solutions: Reviewing topical solutions as for retinal vascular diseases Gene Therapy: Overcoming existing hurdles surrounding the development of Ophthalmic gene therapies and their delivery Durable Formulations: Developing durable formulations for nAMD, DR and DME to achieve longer lasting deliveryRead more

day: Conference Day 2

Evaluating Anti-VEGF Non-Responders in Large Portions of Patient Populations & Treating Underlying Diseases to Prevent Disease Progression into Wet AMD, DME, DR & RVO Patients 2:05 pm

For the past 20 years, the VEGF pathway has been the most exploited and researched therapeutic target for retinal vascular diseases. For majority of the patient population, targeting this pathway with anti-VEGF antibodies has been successful, however, a large portion of patients remain untreated due to anti-VEGF resistance. Join your peers as they discuss: Uncovering…Read more

day: Pre-Conference Workshop